VTVT Rasio cepet vTv Therapeutics, Inc.

The price trajectory of vTv Therapeutics Inc. (VTVT) demonstrates the current indicator 11.87. vTv Therapeutics Inc. (VTVT) develops innovative tablet-based therapies for type 1 diabetes, investing in the study of glucokinase. The business faces intense pressure from global behemoths that restrict market access through patents. The operating model relies on a lean management team and external contractors to conduct clinical trials.

The development of TTP399 for diabetics requires significant expenditures, making it critical to monitor the ability of vTv Therapeutics Inc. (VTVT) to cover short-term obligations using cash and accounts receivable, excluding illiquid inventories. By analyzing the quick liquidity structure, an investor assesses the business's real margin of safety in the face of potential financial shocks and default risks.